MedTrace Logo

Zinc/PSA Ratio as a Novel Biomarker for Prostate Cancer Detection

NCT02013180 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 480

Last updated 2019-04-16

Study results available
· View outcomes & findings →

Summary

Although Prostate Specific Antigen (PSA) is a useful marker for early detection of the prostate cancer, its specivity is not sufficient. Several PSA variations were defined in order to increase the specivity of the test, but they aren't much more effective than the PSA alone for detection of disease.

In older studies reported that, serum and prostatic tissue zinc levels decreased in prostat cancer disease.

In our study we aimed to establish the utility of serum zinc, PSA, free PSA/PSA (fPSA/tPSA), zinc/PSA, levels for early detection of the prostate cancer.

Conditions

  • Prostate Cancer Detection

Sponsors & Collaborators

  • Bagcilar Training and Research Hospital

    lead OTHER_GOV

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2013-01-31
Completion
2017-01-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02013180 on ClinicalTrials.gov